Uropharmacology: XI. Adrenergic-blocking agents and drugs affecting catecholamine binding and release.
D018663:Adrenergic Agents / Q000494:pharmacology*; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000818:Animals; D001949:Bretylium Compounds / Q000494:pharmacology; D004087:Dihydroergotamine / Q000494:pharmacology; D006145:Guanethidine / Q000494:pharmacology; D006801:Humans; D008297:Male; D008750:Methyldopa / Q000494:pharmacology; D009130:Muscle, Smooth / Q000187:drug effects; D010643:Phenoxybenzamine / Q000494:pharmacology; D010646:Phentolamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D014521:Urethra / Q000187:drug effects; D001743:Urinary Bladder / Q000187:drug effects; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy; D014551:Urinary Tract / Q000187:drug effects*; D014555:Urination Disorders / Q000188:drug therapy
D018663:Adrenergic Agents; D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D001949:Bretylium Compounds; D010643:Phenoxybenzamine; D004087:Dihydroergotamine; D008750:Methyldopa; D011433:Propranolol; D010646:Phentolamine; D006145:Guanethidine